Press releases Archives - Pendopharm https://pendopharm.com/news/category/press-releases/ Fri, 06 Feb 2026 18:26:53 +0000 en-CA hourly 1 https://wordpress.org/?v=6.9 Pendopharm Announces the Approval of Yorvipath® (palopegteriparatide injection) for the Treatment of Chronic Hypoparathyroidism in Adults. https://pendopharm.com/news/pendopharm-announces-the-approval-of-yorvipath-palopegteriparatide-injection-for-the-treatment-of-chronic-hypoparathyroidism-in-adults/ Fri, 06 Feb 2026 18:26:48 +0000 https://pendopharm.com/?p=2002 Montreal, February 6, 2026 – Pendopharm, a division of Pharmascience Inc., announced today that Health Canada has granted market authorization for…

The post Pendopharm Announces the Approval of Yorvipath® (palopegteriparatide injection) for the Treatment of Chronic Hypoparathyroidism in Adults. appeared first on Pendopharm.

]]> Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransCon™ PTH in Canada https://pendopharm.com/news/pendopharm-signs-exclusive-distribution-agreement-with-ascendis-pharma-a-s-for-transcon-pth-in-canada/ Tue, 09 Jul 2024 21:34:57 +0000 https://pendopharm.com/?p=1794 Montreal, July 9, 2024 – Pendopharm, a division of Pharmascience Inc., announced today that it has signed an exclusive distribution agreement…

The post Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransCon™ PTH in Canada appeared first on Pendopharm.

]]> Pendopharm renews distribution agreement with Anika Therapeutics Inc. for Cingal®, Monovisc®, and Orthovisc® https://pendopharm.com/news/pendopharm-renews-distribution-agreement-with-anika-therapeutics-inc-for-cingal-monovisc-and-orthovisc/ Thu, 16 May 2024 15:00:00 +0000 https://pendopharm.com/?p=1766 MONTREAL, May 16, 2024 – Pendopharm, a division of Pharmascience Canada (“Pendopharm”), is pleased to announce the renewal of its exclusive…

The post Pendopharm renews distribution agreement with Anika Therapeutics Inc. for Cingal®, Monovisc®, and Orthovisc® appeared first on Pendopharm.

]]> Pendopharm announces the launch of Octasa® 1600 mg tablets in Canada https://pendopharm.com/news/pendopharm-announces-the-launch-of-octasa-1600-mg-tablets-in-canada/ Thu, 06 Apr 2023 15:58:25 +0000 https://pendopharm.com/?p=1711 Pendopharm, a division of Pharmascience Inc., is pleased to announce the recent launch of Octasa® 1600 mg, the highest-strength delayed-release mesalamine…

The post Pendopharm announces the launch of Octasa<sup>®</sup> 1600 mg tablets in Canada appeared first on Pendopharm.

]]> Pendopharm, a division of Pharmascience Inc, is proud to launch SportVisTM to relieve pain and restore function in damaged tendons and ligaments https://pendopharm.com/news/pendopharm-a-division-of-pharmascience-inc-is-proud-to-launch-sportvistm-to-relieve-pain-and-restore-function-in-damaged-tendons-and-ligaments/ Mon, 03 May 2021 16:17:00 +0000 https://pendopharm.com/?p=1657 Montreal, May 3, 2021 – Pendopharm is proud to launch SportVisTM, the first and only hyaluronic acid injection treatment that is…

The post Pendopharm, a division of Pharmascience Inc, is proud to launch SportVis<sup>TM</sup> to relieve pain and restore function in damaged tendons and ligaments appeared first on Pendopharm.

]]>